glp1InjectablePrescription only (US)
LiraglutideBenefits, Dosage & Interactions
Also known as: saxenda, victoza
Liraglutide is a medication classified as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is administered via subcutaneous injection. Liraglutide's primary actions involve mimicking the effects of natural GLP-1, a hormone produced in the gut that plays a role in blood sugar regulation and appetite.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Plasma half-life
~13 h
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Liraglutide in the cited sources. Published ranges are not dosing advice.
Liraglutide compared with similar compounds
| Attribute | Semaglutide | Tirzepatide | Retatrutide | Liraglutide |
|---|---|---|---|---|
| Class | GLP-1 receptor agonist | GIP/GLP-1 dual receptor agonist | GIP/GLP-1/glucagon triple agonist | GLP-1 receptor agonist |
| Route | Subcutaneous once weekly | Subcutaneous once weekly | Subcutaneous once weekly | Subcutaneous once daily |
| Half-life | ~7 days | ~5 days | ~6 days | ~13 hours |
| Evidence grade | Strong | Strong | Moderate | Strong |
| Oral stability | Oral tablet form exists (with SNAC absorption enhancer) | Not orally available | Not orally available | Not orally available |
| Typical published cycle | Ongoing while prescribed | Ongoing while prescribed | Investigational — phase 3 ongoing | Ongoing while prescribed |
| Main studied use | Type 2 diabetes and weight management | Type 2 diabetes and obesity | Obesity (investigational) | Type 2 diabetes and weight management |
References & evidence
Documents the Liraglutide entry is written from. Each number matches an inline marker above.
- [1]A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementPi-Sunyer X, Astrup A, Fujioka K, et al. · New England Journal of Medicine · 2015 · Peer-reviewed · PMID 26132939
- [2]Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesMarso SP, Daniels GH, Brown-Frandsen K, et al. · New England Journal of Medicine · 2016 · Peer-reviewed · PMID 27295427
How to track Liraglutide doses
Liraglutide is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Liraglutide is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Liraglutide comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 13 h, effects and timing shifts show up over days rather than instantly. Review Liraglutide alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Liraglutide dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Liraglutide studied for?
What is Liraglutide?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Liraglutide is a medication classified as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is administered via subcutaneous injection. Liraglutide's primary actions involve mimicking the effects of natural GLP-1, a hormone produced in the gut that plays a role in blood sugar regulation and appetite.
Approved applications for liraglutide vary by dose. At lower doses, it is approved for the treatment of type 2 diabetes mellitus to improve glycemic control in adults and children aged 10 years and older. For this indication, it is often used as an adjunct to diet and exercise. At a higher dose, liraglutide is approved for chronic weight management in adults and adolescents aged 12 years and older who are obese or overweight with at least one weight-related comorbidity, also as an adjunct to diet and exercise.
Liraglutide is available under different brand names depending on its approved use and dosage (e.g., Victoza for type 2 diabetes, Saxenda for weight management). It must be prescribed and managed by a licensed clinician due to its controlled nature and potential side effects.
What does the research say about Liraglutide?
Tap a section to expand.
Liraglutide acts as an analogue of human glucagon-like peptide-1 (GLP-1), with approximately 97% sequence homology to endogenous GLP-1. Its mechanism of action involves binding to and activating the GLP-1 receptor.
Upon activation of GLP-1 receptors, liraglutide exhibits several physiological effects:
* **Glucose-dependent insulin secretion:** Liraglutide stimulates insulin release from pancreatic beta cells when blood glucose levels are elevated. This effect is glucose-dependent, meaning it largely subsides as blood glucose levels decrease, reducing the risk of hypoglycemia compared to some other antidiabetic agents (Source: FDA Prescribing Information).
* **Suppression of glucagon secretion:** It inhibits the release of glucagon from pancreatic alpha cells. Glucagon is a hormone that raises blood glucose, so its suppression helps to lower blood sugar levels.
* **Delay of gastric emptying:** Liraglutide slows down the rate at which food leaves the stomach. This contributes to a feeling of fullness and can reduce post-meal blood glucose excursions.
* **Appetite reduction and increased satiety:** By acting on GLP-1 receptors in the brain, liraglutide influences centers that regulate appetite and food intake, leading to reduced hunger and increased feelings of satiety. This neuroregulatory effect is a key component of its utility in weight management (Source: DrugBank).
The prolonged action of liraglutide compared to endogenous GLP-1 is due to modifications that make it resistant to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and allow it to bind to albumin, extending its circulating half-life.
Source for this section: Sources for How does Liraglutide work?: Jumps to this entry in the sources and references list at the end of the page.
Liraglutide offers distinct benefits across its approved indications:
* **Glycemic Control in Type 2 Diabetes:** For individuals with type 2 diabetes, liraglutide helps to lower HbA1c levels, a measure of average blood sugar over two to three months. It improves fasting and postprandial blood glucose levels. Clinical trials have demonstrated its efficacy in reducing HbA1c, both as monotherapy and in combination with other antidiabetic agents (Source: NIH ODS, MedlinePlus).
* **Weight Reduction:** In individuals with obesity or who are overweight with comorbidities, liraglutide, when used in conjunction with diet and exercise, can lead to significant and sustained weight loss. Studies have shown greater reductions in body weight compared to placebo (Source: Mayo Clinic).
* **Cardiovascular Benefits:** For individuals with type 2 diabetes and established cardiovascular disease, liraglutide has been shown to reduce the risk of major adverse cardiovascular events (e.g., cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) (Source: FDA Prescribing Information).
* **Blood Pressure Reduction:** Some studies have indicated that liraglutide can lead to modest reductions in systolic blood pressure, which is an additional cardiovascular benefit.
* **Lipid Profile Improvement:** Liraglutide may also contribute to improvements in lipid parameters, such as reductions in triglycerides and increases in high-density lipoprotein (HDL) cholesterol, although these effects are typically secondary to weight loss and glycemic control.
* **Kidney Benefits:** In certain populations with type 2 diabetes, liraglutide has shown a reduction in the progression of kidney disease (nephropathy) (Source: DrugBank).
The efficacy and safety of liraglutide have been extensively evaluated in numerous clinical trials, including large-scale, long-term studies.
For **type 2 diabetes**, the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results — A Long Term Evaluation) was a landmark cardiovascular outcomes trial. It demonstrated that liraglutide significantly reduced the risk of the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and high cardiovascular risk compared to placebo when added to standard care (Source: New England Journal of Medicine, referenced by FDA Prescribing Information).
For **weight management**, the SCALE (Satiety and Clinical Adiposity Liraglutide Evidence in Nondiabetic and Diabetic Subjects) clinical trial program provided robust evidence. For instance, the SCALE Obesity and Prediabetes trial showed that non-diabetic individuals receiving liraglutide experienced significantly greater weight loss compared to those receiving placebo over 56 weeks, in combination with a reduced-calorie diet and increased physical activity. A majority of participants achieved clinically significant weight loss of 5% or more of their baseline body weight (Source: The Lancet, referenced by MedlinePlus).
Further evidence from various meta-analyses and systematic reviews, such as those published in Cochrane reviews, supports liraglutide's role in improving glycemic control, facilitating weight loss, and offering cardiovascular protection, particularly in patients with type 2 diabetes at high cardiovascular risk. These analyses consistently show that liraglutide is superior to placebo and comparably effective or superior to some other antidiabetic agents in terms of HbA1c reduction and weight loss.
Like all medications, liraglutide can cause side effects. Many individuals experience gastrointestinal side effects, especially when first starting the medication or increasing the dose. These often lessen over time.
Common side effects (may affect more than 1 in 10 people) include:
* Nausea
* Diarrhea
* Constipation
* Vomiting
Other common side effects (may affect up to 1 in 10 people) can include:
* Headache
* Dizziness
* Indigestion (dyspepsia)
* Abdominal pain
* Fatigue
* Decreased appetite
* Injection site reactions (e.g., redness, itching, swelling)
Serious side effects are less common but require immediate medical attention. These include:
* **Pancreatitis:** Severe pain in the stomach area that may spread to the back, with or without vomiting. This is a rare but serious side effect (Source: EMA SmPC).
* **Gallbladder problems:** Including gallstones that may require surgery.
* **Kidney problems (renal impairment):** Dehydration from severe nausea, vomiting, or diarrhea can sometimes lead to kidney issues.
* **Hypoglycemia (low blood sugar):** While less common with liraglutide alone due to its glucose-dependent action, it can occur, especially when used in combination with sulfonylureas or insulin (Source: FDA Prescribing Information).
* **Allergic reactions:** Swelling of the face, lips, tongue, or throat, difficulty breathing, severe rash, or rapid heartbeat.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Several important warnings are associated with the use of liraglutide:
* **Thyroid C-cell Tumors and Medullary Thyroid Carcinoma (MTC):** Liraglutide has caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether liraglutide causes thyroid C-cell tumors, including MTC, in humans. Liraglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled on the potential risk of MTC and symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness) (Source: FDA Prescribing Information).
* **Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide. If pancreatitis is suspected, liraglutide should be discontinued, and appropriate management initiated. It is unknown if patients with a history of pancreatitis are at increased risk for pancreatitis while using liraglutide (Source: MedlinePlus).
* **Gallbladder Disease:** Acute gallbladder disease (cholelithiasis, cholecystitis) has been reported in GLP-1 receptor agonist trials. Significant weight loss can also increase the risk of gallstones.
* **Kidney Impairment:** There have been postmarketing reports of acute kidney failure and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, including liraglutide. Some of these events were reported in patients without known underlying renal disease. Most of the reported events occurred in patients who experienced nausea, vomiting, or diarrhea leading to volume depletion.
* **Hypoglycemia:** The risk of hypoglycemia is increased when liraglutide is used in combination with a sulfonylurea or insulin. A dose reduction of the concomitant sulfonylurea or insulin may be necessary.
* **Hypersensitivity Reactions:** Serious hypersensitivity reactions (e.g., anaphylactic reactions, angioedema) have been reported.
* **Diabetic Retinopathy Complications:** In patients with type 2 diabetes, rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored.
* **Acute Heart Rate Increase:** Liraglutide is associated with an increase in resting heart rate. Patients should be informed of symptoms of increased heart rate and advised to seek medical attention if symptoms persist or worsen.
* **Suicidal Ideation and Behavior:** In clinical trials, suicidal ideation has been reported. Patients should be monitored for changes in mood or behavior, and liraglutide should be discontinued if such changes occur.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Liraglutide is contraindicated in certain medical conditions due to significant risks:
* **Personal or Family History of Medullary Thyroid Carcinoma (MTC):** Due to the potential risk of thyroid C-cell tumors observed in animal studies, liraglutide is contraindicated in patients with a personal history of MTC or a family history of MTC.
* **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2):** Patients with MEN 2 are at an increased risk of MTC, therefore liraglutide is contraindicated in this population.
* **Prior Serious Hypersensitivity Reaction to Liraglutide or any Excipients:** Any history of severe allergic reaction (e.g., anaphylaxis, angioedema) to liraglutide or its components is a contraindication.
* **Pregnancy:** Liraglutide is not recommended for use during pregnancy, as animal studies have shown potential harm to the fetus. The benefits of glycemic control in pregnant women must be carefully weighed against potential risks to the fetus. Alternative treatments are generally preferred.
* **Breastfeeding:** It is unknown whether liraglutide is excreted in human milk. Due to potential undesirable effects on the breastfed infant, a decision should be made whether to discontinue nursing or discontinue liraglutide, taking into account the importance of the drug to the mother (Source: DrugBank).
* **Diabetic Ketoacidosis:** Liraglutide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it is not a substitute for insulin.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While liraglutide can be used in combination therapy for type 2 diabetes, certain precautions and potential interactions should be considered:
* **Other GLP-1 Receptor Agonists:** Liraglutide should not be used in combination with other GLP-1 receptor agonists (e.g., semaglutide, dulaglutide) due to additive effects and increased risk of side effects without additional benefit (Source: Clinically relevant information from MedlinePlus).
* **Insulin Secretagogues (e.g., Sulfonylureas) and Insulin:** When co-administered with sulfonylureas or insulin, there is an increased risk of hypoglycemia. Clinicians typically recommend a dose reduction of the sulfonylurea or insulin to mitigate this risk. Patients using these combinations must monitor blood glucose levels closely.
* **Oral Medications with a Narrow Therapeutic Index:** Due to its effect on gastric emptying, liraglutide has the potential to affect the absorption of concomitantly administered oral medications. While this effect is generally considered clinically insignificant for most oral drugs, caution is advised for medications with a narrow therapeutic index where small changes in absorption could have significant consequences (e.g., warfarin, digoxin). Increased monitoring may be warranted for such drugs (Source: EMA SmPC).
* **Other Weight Loss Medications:** Liraglutide used for weight management should generally not be combined with other prescription medications specifically approved for weight loss, unless under direct medical supervision and careful consideration of potential additive effects and risks (Source: General pharmacological principle).
Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to ensure safe and effective treatment.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Liraglutide is administered once daily via subcutaneous injection. The specific timing of the injection is flexible, meaning it can be administered at any time of day, with or without regard to meals. Consistency in administration time, however, may help patients incorporate it into their daily routine.
For example, some individuals may prefer to administer it in the morning, while others might choose the evening, depending on their personal schedule and how they experience potential side effects like nausea. It is important to inject liraglutide into the abdomen, thigh, or upper arm. The injection sites should be rotated within the same region to avoid localized skin reactions.
The dose of liraglutide is user-directed and must be set by a licensed clinician. The starting dose is typically low and is gradually increased over several weeks. This titration schedule is crucial to minimize gastrointestinal side effects.
Source for this section: Sources for When should you take Liraglutide?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Liraglutide?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Insulin (Rapid) | Caution | Compound pairConfidence: theoretical | Combining a GLP-1 with rapid insulin increases hypoglycemia risk.Source pending | Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely. |
| Insulin (Long-Acting) | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
Frequently asked questions about Liraglutide
No, liraglutide is not approved for the treatment of type 1 diabetes mellitus. It is designed to work by stimulating insulin production from the pancreas in a glucose-dependent manner, a function that is absent or severely impaired in type 1 diabetes. Individuals with type 1 diabetes require insulin replacement therapy.
Weight loss with liraglutide is gradual. Clinical studies typically show meaningful weight loss occurring over several weeks to months, with significant results often observed after 12 to 16 weeks of treatment at the full maintenance dose, and continued loss over a year. Individual results can vary.
If you miss a dose of liraglutide, take it as soon as you remember, unless more than 12 hours have passed since your usual dosing time. In that case, skip the missed dose and resume your regular dosing schedule with the next planned dose. Do not take a double dose to make up for a missed one. Always consult your prescribing clinician or pharmacist for personalized advice.
Yes, pancreatitis is a rare but serious side effect associated with GLP-1 receptor agonists, including liraglutide. Symptoms include severe, persistent stomach pain that may radiate to the back, with or without vomiting. If you experience these symptoms, discontinue liraglutide and seek immediate medical attention (Source: FDA Prescribing Information).
No, liraglutide is not insulin. It is a GLP-1 receptor agonist, which works by mimicking natural GLP-1 to stimulate the body's own insulin production when blood sugar is high, suppress glucagon, slow gastric emptying, and reduce appetite. While it affects insulin levels, it does not directly replace insulin.
Interaction risk for Liraglutide comes from the rest of the stack: other supplements, prescription medicines, hormone therapy and peptides. With a reported plasma half-life near 13 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Liraglutide with no sign-up.
There is no single answer for Liraglutide plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Liraglutide with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 13 hours, once-daily dosing is the usual pattern for Liraglutide. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
For an injectable like Liraglutide the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Liraglutide?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes(opens PubMed in a new tab)N Engl J Med · 2016 · PMID 27295427 · https://pubmed.ncbi.nlm.nih.gov/27295427/
- 2.Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial(opens PubMed in a new tab)JAMA · 2022 · PMID 35015037 · https://pubmed.ncbi.nlm.nih.gov/35015037/
- 3.Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial(opens PubMed in a new tab)N Engl J Med · 2025 · PMID 39258838 · https://pubmed.ncbi.nlm.nih.gov/39258838/
- 4.Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined(opens PubMed in a new tab)N Engl J Med · 2021 · PMID 33951361 · https://pubmed.ncbi.nlm.nih.gov/33951361/
- 5.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study(opens PubMed in a new tab)Lancet · 2016 · PMID 26608256 · https://pubmed.ncbi.nlm.nih.gov/26608256/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 16134956(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/16134956
Verify at
Publisher search links for Liraglutide. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Liraglutide?
Plain-text summary, safe to quote verbatim:
Liraglutide is a medication classified as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is administered via subcutaneous injection. Liraglutide's primary actions involve mimicking the effects of natural GLP-1, a hormone produced in the gut that plays a role in blood sugar regulation and appetite.
Source: DoseRoutine — https://doseroutine.com/library/liraglutide
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Liraglutide — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/liraglutide
What compounds are similar to Liraglutide?
Others in the glp1 category or studied for the same goals.
Which goals is Liraglutide used for?
Other compounds studied for the same benefits as Liraglutide.
Continue exploring
See every compound DoseRoutine catalogs for these goals.